News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
823,540 Results
Type
Article (76191)
Company Profile (647)
Press Release (746702)
Multimedia
Podcasts (128)
Webinars (14)
Section
Business (228948)
Career Advice (3783)
Deals (39369)
Drug Delivery (129)
Drug Development (89688)
Employer Resources (198)
FDA (17924)
Job Trends (17188)
News (389925)
Policy (38989)
Tag
Academia (2999)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (56324)
ALS (104)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17879)
Artificial intelligence (312)
Autoimmune disease (29)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (440)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2482)
Cardiovascular disease (210)
Career advice (3224)
Career pathing (34)
CAR-T (176)
Cell therapy (497)
Cervical cancer (22)
Clinical research (72502)
Collaboration (935)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2361)
Decentralized trials (2)
Denatured (45)
Depression (56)
Diabetes (302)
Diagnostics (6924)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (135)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (94947)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (129452)
Executive appointments (788)
FDA (19353)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (30)
Gene therapy (365)
GLP-1 (860)
Government (5146)
Grass and pollen (6)
Guidances (150)
Healthcare (20878)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (742)
IPO (17760)
IRA (51)
Job creations (5038)
Job search strategy (2633)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9960)
Liver cancer (82)
Lung cancer (349)
Lymphoma (161)
Machine learning (9)
Management (65)
Manufacturing (367)
MASH (81)
Medical device (14626)
Medtech (14631)
Mergers & acquisitions (22176)
Metabolic disorders (806)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (117)
Neuropsychiatric disorders (34)
Neuroscience (2122)
NextGen: Class of 2025 (7641)
Non-profit (5082)
Now hiring (41)
Obesity (433)
Opinion (275)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (64465)
Pharmaceutical (136)
Pharmacy benefit managers (22)
Phase I (22398)
Phase II (31606)
Phase III (23828)
Pipeline (1397)
Policy (180)
Postmarket research (3301)
Preclinical (9949)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (437)
Real estate (7211)
Recruiting (75)
Regulatory (26255)
Reports (58)
Research institute (2655)
Resumes & cover letters (589)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (27)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4209)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (306)
Women's health (40)
Worklife (20)
Date
Last 7 days (989)
Last 30 days (3171)
Last 365 days (34964)
2025 (12602)
2024 (37929)
2023 (42567)
2022 (53927)
2021 (58723)
2020 (57665)
2019 (51318)
2018 (39102)
2017 (36916)
2016 (37887)
2015 (43902)
2014 (38729)
2013 (34881)
2012 (36713)
2011 (36809)
2010 (36472)
Location
Africa (1208)
Alabama (61)
Alaska (7)
Arizona (253)
Arkansas (14)
Asia (48881)
Australia (8394)
California (6681)
Canada (2107)
China (575)
Colorado (289)
Connecticut (305)
Delaware (167)
Europe (111006)
Florida (977)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (628)
India (30)
Indiana (342)
Iowa (12)
Japan (178)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (993)
Massachusetts (5108)
Michigan (250)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (70)
New Jersey (1878)
New Mexico (31)
New York (1877)
North Carolina (1142)
North Dakota (9)
Northern California (2877)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1464)
Puerto Rico (14)
Rhode Island (36)
South America (1580)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (995)
United States (25463)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (612)
West Virginia (3)
Wisconsin (70)
823,540 Results for "vetter pharma fertigung gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vetter Prioritizes Continuity and Action in its Sustainability Efforts
May 6, 2025
·
1 min read
Press Releases
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 15, 2024
·
3 min read
Press Releases
Vetter Boosts Pharmaceutical Storage Capacity with Major Warehouse Expansion
March 11, 2025
·
1 min read
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 21, 2025
·
5 min read
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents
March 26, 2024
·
4 min read
Vetter Becomes a Member of the German Association of Research-Based Pharmaceutical Companies (vfa)
Globally operating CDMO committed to strengthening Germany as a research and production location Association grants Vetter extraordinary membership vfa recognizes the importance of pharmaceutical service providers in drug development and production Vetter serves on key vfa committees RAVENSBURG, Germany--( BUSINESS WIRE )-- Vetter, a leading globally operating contract development and manufacturing organization (CDMO), has joined the German Association o
January 17, 2024
·
4 min read
Deals
Luciole Medical AG Announces the Acquisition of Spiegelberg GmbH & Co. KG to Create a Leading Global Brain Monitoring Developer and Provider
Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.
June 27, 2023
·
4 min read
Press Releases
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
April 7, 2025
·
2 min read
Business
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
May 28, 2024
·
2 min read
1 of 82,354
Next
